Impact of angiographic coronary artery disease complexity on ischemic and bleeding
risks and on the comparative effectiveness of zotarolimus-eluting vs. bare-metal stents
in uncertain drug-eluting stent candidates
Background: The impact of coronary artery disease (CAD) extension/complexity on outcomes
and on the comparative benefits/risks of zotarolimus-eluting stent (ZES) versus bare-metal
stents (BMS) remains unclear in patients at high risk of bleeding or thrombosis or
at low restenosis risk.